- Record: found
- Abstract: found
- Article: not found
In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.
Klaus P Hoeflich
1 ,
Carol O'Brien ,
Zachary Boyd ,
Guy Cavet ,
Steve Guerrero ,
Kenneth Jung ,
Tom Januario ,
Heidi Savage ,
Elizabeth Punnoose ,
Tom Truong ,
Wei Zhou ,
Leanne Berry ,
Lesley Murray ,
Lukas Amler ,
Marcia Belvin ,
Lori S Friedman ,
Mark R Lackner
Jul 15 2009
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
The pathways underlying basal-like breast cancer are poorly understood, and as yet, there is no approved targeted therapy for this disease. We investigated the role of mitogen-activated protein kinase kinase (MEK) and phosphatidylinositol 3-kinase (PI3K) inhibitors as targeted therapies for basal-like breast cancer.